Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Recipient : Mundipharma
Deal Size : Undisclosed
Deal Type : Collaboration
Mundipharma and Vectura announce plans to reformulate flutiform®
Details : The collaboration aims to reformulate flutiform (fluticasone propionate/formoterol fumarate) used in a pressurised metered-dose inhaler. It is being indicated for asthma.
Product Name : Flutiform
Product Type : Steroid
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Fluticasone Propionate,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Recipient : Mundipharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Biophytis and Skyepharma Sign a Partnership Agreement for The Production of Sarconeos (BIO101)
Details : Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.
Product Name : Sarconeos
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : 20-Hydroxyecdysone
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Biophytis
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : MaaT013
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : MaaT Pharma
Deal Size : Undisclosed
Deal Type : Partnership
MaaT and Skyepharma Partner for First Microbiome cGMP Site in France
Details : Through the parternship, MaaT Pharma will increase the manufacturing capacities ten-fold in order to support clinical and commercial development of MaaT013 for the treatment of GvHD.
Product Name : MaaT013
Product Type : Protein
Upfront Cash : Undisclosed
February 08, 2022
Lead Product(s) : MaaT013
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : MaaT Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Cannabidiol,Isoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicolog...
Product Name : IHL-216A
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 22, 2021
Lead Product(s) : Cannabidiol,Isoflurane
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Incannex Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : IPA-001
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inspira
Deal Size : Undisclosed
Deal Type : Agreement
Vectura, Inspira Pharmaceuticals Team Up to Develop Potential Inhaled COVID-19 Treatment
Details : IPA-001 is inhaled formulation displayed viricidal activity against SARS-CoV2 after 5 minutes contact time. It is purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 ...
Product Name : IPA-001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 05, 2021
Lead Product(s) : IPA-001
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inspira
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Vectura Highlights Update Made by Hikma on Launch of Generic Advair Diskus®
Details : Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.
Product Name : Fluticasone Propionate/Salmeterol-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
April 21, 2021
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : $95.0 million
Deal Type : Agreement
Vectura Earns $11m Milestone as Hikma Receives US FDA Approval for Generic Advair Diskus®
Details : The new device is an evolution of Vectura’s lever-operated multi-dose (LOMI) device and builds on Vectura and Hikma’s shared experience with the generic Advair Diskus® programme, enabling accelerated development under this agreement.
Product Name : Fluticasone Propionate/Salmeterol-Generic
Product Type : Steroid
Upfront Cash : $15.0 million
December 17, 2020
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : $95.0 million
Deal Type : Agreement
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fluticasone Propionate / Salmeterol or VR315 is a generic, inhaled combination therapy for asthma/COPD delivered using Vectura's proprietary dry powder inhaler and formulation technology.
Product Name : Fluticasone Propionate/Salmeterol-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
September 22, 2020
Lead Product(s) : Fluticasone Propionate,Salmeterol Xinafoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Sponsor : Monash University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Vectura will support the development of a single use device/formulation combination for evaluation in Phase I of inhaled oxytocin, and then expedite technical transfer to a commercial manufacturer to advance to Phase III and commercial launch.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
September 14, 2020
Lead Product(s) : Oxytocin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Sponsor : Monash University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : IND Enabling
Sponsor : Aerami Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Vectura Signs Agreement with Aerami Therapeutics Inc
Details : Aerami will be responsible for the overall development and commercialisation of inhaled imatinib, with Vectura providing development services expertise and a license to its FOX® mesh nebuliser technology.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 06, 2020
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Sponsor : Aerami Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
KEY SERVICES
Reset All
